Profitelligence Profitelligence · Filing Ledger Open AMGN research →

Form 8-K · Current Report · Filed 2026-05-20

Amgen Inc. Announces Results of Annual Meeting of Stockholders

Amgen Inc. held its Annual Meeting on May 19, 2026, where all 12 nominees for director were elected to serve a one-year term. The advisory vote to approve executive compensation was approved, and Ernst & Young LLP was ratified as the Company's independent registered public accountants for the fiscal year ending December 31, 2026. The stockholder proposal to require an independent board chairman was not approved.

Filer
Amgen Inc. AMGN · NASDAQ
Filed
Accession
0001193125-26-232786
CIK
0000318154
Signal
Medium impactHealthcare

Items reported

Item events

Reported Item

Board Member Appointed Stock Plan Modification Audit Firm Change

Market reaction

Close before filing

$330.75

Next session

+2.0%

Since filing

+16.5%

Latest close

$385.16

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from AMGN reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, AMGN insiders reported 59 Form 4 transactions — net buying of $67.9M.

Full AMGN insider history →

About Amgen Inc.

Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.

Exchange NASDAQ Industry Drug Manufacturers - General Company website ↗

Never miss another AMGN filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts